StockData
Veradermics, Inc logo

Veradermics, Inc (MANE) stock

MANENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$125.64−2.41 (-1.88%)

Close on Nov 17, 2026Market cap $5.25BP/E –Yield –

Veradermics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$72.35M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$72.35M–
FY2024Dec 31, 2024-$26.78M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$29.55M–
Q1 FY2026Mar 31, 2026-$29.86M–
Q2 FY2025Jun 30, 2025-$16.07M–
Q1 FY2025Mar 31, 2025-$12.92M–

More Veradermics figures

See a number that looks wrong?